FISCHERFischer Medical Ventures Limited
Healthcare · Medical Devices · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosks; e-health access points; software solutions; cancer, TB screening, and handheld x-ray; spincare technology; nutraceuticals from plant extracts; mental health solutions; contactless screening solutions; and CT scan systems, as well as preventive diagnostic devices and ancillary medical instruments. The company was formerly known as Fischer Chemic Limited and changed its name to Fischer Medical Ventures Limited in March 2024. Fischer Medical Ventures Limited was incorporated in 1993 and is headquartered in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 36/100)
- • ROE: 8.4%
- • ROCE: 8.2%
- • RSI: 35
- • MACD: bearish
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 249.4% YoY
- • Profit growth: 2076.4% YoY
- • Debt/Equity: 0.28
- • Trend strength (ADX): 32
Bear case
- • ROE: 8.4%
- • ROCE: 8.2%
- • RSI: 35
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • ROE: 8.4%
- • ROCE: 8.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.19). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.